Geode Capital Management
SGP

Geode Capital Management’s SpyGlass Pharma SGP Stock Holding History

Geode Capital Management’s Portfolio SGP Stock Details SGP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.18M Buy
277,325
+150,785
+119% +$3.27M ﹤0.01% 2809
2026
Q1 		$3.28M Buy
+126,540
New +$3.4M ﹤0.01% 2929

Other funds holding SGP

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management's SGP Position: Q2 2026 in Review

Geode Capital Management increased its SpyGlass Pharma (SGP) stake by 119% in Q2 2026, buying an estimated $3.27M and bringing the position to 277,325 shares worth $6.18M. The position accounts for ﹤0.01% of the portfolio, ranked #2809.

Geode Capital Management first reported a position in SGP in Q1 2026 and has held it in 2 quarters since. 43 funds tracked by Wall St. Rank hold SGP as of Q2 2026.

  • Geode Capital Management held 277,325 shares of SpyGlass Pharma worth $6.18M as of Q2 2026.
  • Geode Capital Management bought 150,785 SpyGlass Pharma shares in Q2 2026, an estimated $3.27M.
  • SpyGlass Pharma made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2809 holding.
  • Geode Capital Management first reported a position in SpyGlass Pharma in Q1 2026 and has held it in 2 quarters since.
  • 43 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.